Clinical Trial News and Research

RSS

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the first quarter ended March 31, 2014.

17 May 2014

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.

16 May 2014

Kamada announces top-line results from Phase II/III trial for treatment of inherited emphysema

Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announces preliminary top-line results from the Phase II/III pivotal clinical trial in Europe and Canada of the Company's proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or inherited emphysema).

16 May 2014

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has successfully completed a Phase II trial, conducted under an IND, of Vesimune (TMX-101) in CIS (carcinoma in situ) of the bladder.

16 May 2014

Anticoagulation therapy with low-dose aspirin can be used with new generation mechanical heart valve

Less aggressive anticoagulation therapy, combined with low-dose aspirin, can be used safely in conjunction with a newer generation mechanical heart valve.

16 May 2014

New dual-pronged approach for treating Niemann-Pick type C disease

By studying nerve and liver cells grown from patient-derived induced pluripotent stem cells (iPSCs), Whitehead Institute researchers have identified a potential dual-pronged approach to treating Niemann-Pick type C (NPC) disease, a rare but devastating genetic disorder.

16 May 2014

NovaBay completes enrollment of patients in global Phase 2b viral conjunctivitis trial

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing non-antibiotic, topical antimicrobial products, today announced it has completed enrollment of patients in its global Phase 2b viral conjunctivitis trial, BAYnovation.

16 May 2014

CHOP oncologist receives Lifetime Achievement Award at ANRA association's international meeting

The Advances in Neuroblastoma Research Association (ANRA) is conferring its highest honor on pediatric oncologist Garrett M. Brodeur, M.D., of the Cancer Center at The Children's Hospital of Philadelphia (CHOP).

16 May 2014

Researchers test genomic sequencing for women with triple negative breast cancer

Indiana University cancer researchers are testing whether therapy incorporating advanced genomic technology will provide better outcomes than current treatments for those with an aggressive form of breast cancer.

15 May 2014

Inspire Medical Systems completes $40 million Series E financing

Inspire Medical Systems, Inc. announced today that it has completed a Series E financing of $40 million. The financing round was strategically timed to coincide with the commercial launch of the Inspire Upper Airway Stimulation (UAS) therapy in the United States.

15 May 2014

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that principal investigator, Srdan Verstovsek, MD, PhD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 2, 2014 at the American Society for Clinical Oncology 2014 Annual Meeting.

15 May 2014

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results and operational highlights for the quarter ended March 31, 2014.

15 May 2014

Virtualscopics reports record revenues in first quarter 2014

VirtualScopics, Inc., a leading provider of quantitative imaging solutions, today reported the financial results for the first quarter ended March 31, 2014.

15 May 2014

Kamada to present Phase 2/3 clinical trial results of AAT to treat alpha-1 antitrypsin deficiency

Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, will announce results from its Phase 2/3 clinical trial of its proprietary inhaled alpha-1 antitrypsin (AAT) to treat alpha-1 antitrypsin deficiency (AATD) in Europe and Canada on Friday, May 16, 2014, at approximately 7:30 a.m. Eastern time.

15 May 2014

Novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis

A novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis (PVNS), a rare neoplastic joint disorder, according to new phase I data from Memorial Sloan Kettering Cancer Center and other institutions highlighted to media today in advance of the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will take place from May 30 to June 3 in Chicago.

15 May 2014

‘Lessebo’ effect implications for Parkinson’s therapies

Patients with Parkinson’s disease have a reduced objective response to treatment given in a clinical trial if they know they may be taking a placebo, research shows.

14 May 2014

Retrophin reports net loss of $70.6 million for first quarter 2014

Retrophin, Inc. today reported its financial results for the quarter ended March 31, 2014.

14 May 2014

Aradigm reports total revenue of $6.6 million for Q1 2014

Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2014.

14 May 2014

Eagle Pharmaceuticals total revenue increases by $2.5 million for Q2 2014

Eagle Pharmaceuticals, Inc. today announced its financial results for the three-month period ended March 31, 2014. This marks the first period for which Eagle is reporting financial results as a public company.

14 May 2014

Minimally invasive TAVR procedure saves more lives than open-heart surgery, shows study

For the first time, a minimally invasive transcatheter valve - tested by Baylor Research Institute in Dallas (BRI) - has been shown to save more lives than open-heart surgery, according to new research revealed at the American College of Cardiology's 2014 Scientific Sessions and published in The New England Journal of Medicine.

From Medtronic 14 May 2014

Clinical Trial News and Research

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Kamada announces top-line results from Phase II/III trial for treatment of inherited emphysema

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

Anticoagulation therapy with low-dose aspirin can be used with new generation mechanical heart valve

New dual-pronged approach for treating Niemann-Pick type C disease

NovaBay completes enrollment of patients in global Phase 2b viral conjunctivitis trial

CHOP oncologist receives Lifetime Achievement Award at ANRA association's international meeting

Researchers test genomic sequencing for women with triple negative breast cancer

Inspire Medical Systems completes $40 million Series E financing

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

Virtualscopics reports record revenues in first quarter 2014

Kamada to present Phase 2/3 clinical trial results of AAT to treat alpha-1 antitrypsin deficiency

Novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis

‘Lessebo’ effect implications for Parkinson’s therapies

Retrophin reports net loss of $70.6 million for first quarter 2014

Aradigm reports total revenue of $6.6 million for Q1 2014

Eagle Pharmaceuticals total revenue increases by $2.5 million for Q2 2014

Minimally invasive TAVR procedure saves more lives than open-heart surgery, shows study

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer